Gale Lab




Hepatitis C virus

Hepatitis C virus mediates chronic infection in 2% of the world population, and is a major etiology of liver disease; infection is treated through injection of alpha interferon. Our studies are currently focused on defining the processes by which hepatitis C virus suppresses innate immunity and interferon actions to persist in the infected cell. We have identified the viral interface with the RIG-I pathway and specific interferon-stimulated genes as major determinants of hepatitis C virus infection outcome. Current studies are focused on defining the molecular mechanisms by which the RIG-I pathway, interferon signaling, and therapeutic interferon actions are governed during hepatitis C virus infection.

Geographic distribution of Hepatitis C Virus HCV Incidences, Globally
HepC Progression
Human Liver Cells with Chronic HCV Infection
Hepatitis C Virus Genome
Hepatitis C Genome


Hepatitis C Virus Information:

CDC: Hepatitis C
MedlinePlus: Hepatitis C
NIAID: Hepatitis C
HCV Advocate
Washington State Department of Health: Hepatitis C

Research Projects:
The Host Response to Hepatitis C Virus
These studies will complement existing projects in the Gale laboratory that are focused on developing improved HCV culture systems and understanding the role of the viral proteins and host interferon stimulating genes in controlling HCV infection and pathogenesis. 

Innate Immune Defense Against HCV and HIV: The Chimeric Mouse Model
This project aims to define the molecular processes, and identify novel therapeutic targets, within the virus/host interface that regulate the host response to HCV and control infection outcome in a chimerical mouse model in vivo system. The project is also focused on defining the innate immune correlated that regulate HIV infection in vitro and to develop a dual infection model in the chimeric mouse in vivo.

Center for the Study of Innate Immunity to HCV Infection
This center is comprised of experts in the areas of HCV immunobiology, virology, and clinical care; studies are focused on innate immunity, hepatic immunology, and interferon anti-viral therapy to HCV infection. This research will broaden our understanding of the virus/host interactions of hepatitis C virus (HCV) that regulate innate immunity, therapy, and the outcome of infection.